Cartesian Therapeutics, Inc. — Director's Dealing 2017

Jun 28, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2017-06-27

Reporting Person: SPRINGER TIMOTHY A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-27	Common Stock	P	338791	$17.71	Acquired	355413	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-27	Warrant (right to buy)	$17.71	P	79130	Acquired	2022-06-27	Common Stock (79130)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1237028	Indirect
Common Stock	445576	Indirect

Footnotes

F1: LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F2: Held by Leukon Investments LP ("Leukon").

F3: Held by TAS Partners, LLC ("TAS").